Table 4 Effect of comorbidities on patients’ outcome
From: Safety and efficacy of tocilizumab in critically ill patients with COVID-19: an observational study
Outcome | X2* | P value | |||||
|---|---|---|---|---|---|---|---|
Died | Discharged | ||||||
N | % | N | % | ||||
Diabetic | No | 4 | 17.4% | 19 | 82.6% | 1.02 | 0.31 NS |
Yes | 8 | 29.6% | 19 | 70.4% | |||
Hypertensive | No | 3 | 14.3% | 18 | 85.7% | 1.87 | 0.17 NS |
Yes | 9 | 31.0% | 20 | 69.0% | |||
Liver cirrhosis or HCV | No | 10 | 22.7% | 34 | 77.3% | 0.33 FE | 0.62 NS |
Yes | 2 | 33.3% | 4 | 66.7% | |||
Chronic kidney disease | No | 9 | 21.4% | 33 | 78.6% | 0.95 | 0.33 NS |
Yes | 3 | 37.5% | 5 | 62.5% | |||
Ischemic heart disease | No | 7 | 17.9% | 32 | 82.1% | 3.56 | 0.06 NS |
Yes | 5 | 45.5% | 6 | 54.5% | |||
Chronic pulmonary disease | No | 8 | 20.0% | 32 | 80.0% | 1.75 | 0.19 NS |
Yes | 4 | 40.0% | 6 | 60.0% | |||
Smoking | No | 4 | 16.0% | 21 | 84.0% | 1.754 | 0.185NS |
Yes | 8 | 32.0% | 17 | 68.0% | |||